

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	08/109,045 MAR 4, 2001
Filing Date	November 12, 2000
First Named Inventor	M. Rignon Lentz
Group Art Unit	
Examiner Name	
Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examine
Signature

Date
Considered

10/2/02

*** EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if

Kind of document, by the appropriate symbols as indicated on the document under WIPO Standard ST. If it is possible, Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

		Complete if Known	
		Application Number	09/709,045
		Filing Date	November 12, 2000
		First Named Inventor	M. Rignon Lenz
		Group Art Unit	1647
		Examiner Name	J. Schneideweyer
		Attorney Docket Number	LEN 102

OIPE MAR 08 2001 P A T E N T & T R A D E M A R K O F F I C E

MAILED MAR 10 2001 P A T E N T & T R A D E M A R K O F F I C E

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-PS		ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma," <i>J Immunol</i> 144:2582-2591 (1990).	/
		CHEN, et al., "Soluble TNF-a receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	/
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	/
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	/
		EY, et al., "Isolation of pure IgG, IgG _{2a} , and IgG _{2b} , immunoglobulins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	/
		FEINMAN, et al., "Tumor necrosis factor is a important mediator of tumor cell killing by human monocytes," <i>J Immunol</i> 138:635 (1987).	/
		GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9:225-9 (1990).	/
		HARANAKA, et al., "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro," <i>Jpn J Exp Med</i> 51:191 (1981).	/
		Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al.,p. 263 (J.B.Lippincott, Philadelphia, PA 1987).	/
		HOWARD, et al., "Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180:633-664 (1991).	/

Examiner's Signature	<i>gjell</i>	Date Considered	10/21/02
----------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	OIPE SC1985 MAR 08 2001	09/709,045 November 12, 2000
Filing Date	PATENT & TRADEMARK OFFICE	
First Named Inventor	M. Rignon Lenz	
Group Art Unit	164+	
Examiner Name	J. Schatzkes, Jr.	
Attorney Docket Number	LEN 102	

MAIL DATE CANCELLED
MAR 07 2001
PATENT & TRADEMARK OFFICE

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T?
/CMW/		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch. Immunol. Ther. Exp. (Warsz)</i> 45(5-6):449-453 (1997).	✓
		KABAT, et al., <i>Sequences of Proteins of Immunological Interest</i> 4 th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	✓
		LANGKOPF, et al., "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344:57-58 (1994).	✓
		MATHIAS, et al., "Activation of the Sphingomyelin signalling pathway intact EL4 cells and in a cell-free system by IL-1b," <i>Science</i> 259:519-522 (1993).	✓
		MATSCHINER, et al., <i>Current Advances in Vitamin K Research</i> , pp. 135-140, John W. Suttle, ed. (Elsevier Science Publishing Co., Inc. 1988).	✓
		OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): <i>Tumor Necrosis Factor/Cachexin and Related Cytokines</i> , Basel, Karger, p7 (1988).	✓
		PHILIP, et al., "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323:86 (1986).	✓
↓		URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," <i>Proc Natl Acad Sci USA</i> 83:5233 (1986).	✓
/CMW/		ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," <i>Cancer Res</i> 46:5947 (1986).	✓

Examiner's Signature	<i>G. DeLisi</i>	Date Considered	10/2/02
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2
Examiner Name: J. SENEREACYUN
Attorney Docket Number: LEN 102

Complete if Known

RECEIVED

TECH CENTER 1600/2000

Application Number	09/709,045 MAR - 4 2002
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	J. SEVERASEYUN
Attorney Docket Number	LEN 102

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Signature G. L. Elmer Date Considered 10/1/02

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if Foreign language text is present.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent Applications, USPTO, 1401 L Street, NW, Washington, DC 20591.

ATL-1 #505387 v1

LEN 102
077838 00006



Please a plus sign (+) inside this box —

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)

Page # 11

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheo

1

1

Complete If Known	
Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	1647
Examiner Name	J. Schreiber
Attorney Docket Number	LEN 102

U.S. PATENT DOCUMENTS

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

**Examine
Signature**

G. Zehley

Date Considered

18116102

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number? See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if applicable. ⁵ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

/Cherie M. Woodward/ 12/13/2011

ATL1 #545995 v1

LEN 102
077829-00006